Zeynep Mine YALÇINKAYA KARA, Erdinç SERİN, İsmail DAĞ, Özden SERİN

Pre-diyabetik ve yeni tanı almış tip 2 diyabetli hastalarda serum apelin-36 düzeyleri

Amaç: Bu çalışmada, açlık glukozu (IFG), bozulmuş glukoz toleransı (IGT) ve yeni tanı almış tip 2 DM olarak gruplandırılmış hastalarda; glukoz metabolizması ve kardiyovasküler risk faktörleri parametreleri ve apelin-36 düzeylerini araştırılması amaçlanmıştır..Gereç ve Yöntem: Elli üç kadın ve yirmi yedi erkek, toplam seksen katılımcı bu çalışmaya dahil edildi. Orak glükoz tolerans testi (OGTT) sonuçlarına göre hastalar dört gruba ayrıldı. Grup 1: Normoglisemik kontroller (n: 20), Grup2: IFG'li hastalar (n: 20), Grup3: IFG ve IGT'li hastalar (n: 20), Grup4: Yeni tanı almış tip 2 DM hastaları (n: 20). Glikoz, lipidler, HbA1c, fibrinojen, insülin, kortizol, C-peptid ve Apelin-36 seviyeleri analiz edildi.Bulgular: Apelin-36 düzeylerinde grup 1 ile çalışma grupları 2,3 ve 4 arasında istatistiksel olarak anlamlı bir fark vardı). Glukoz metabolizması ve kardiyovasküler risk faktörleri için analiz edilen açlık glukozu, HbA1c, HOMA-IR, fibrinojen, insülin, kortizol, C-peptid, LDL-kolesterol, HDL-kolesterol, VLDL-kolesteroll, triglisterit, total kolesterol gibi parametreler çalışma grubu ile kontrol grubu karşılaştırıldığında anlamlı bir fark bulunduSonuç: Gelecekte serum apelin-36 düzeylerinin erken dönemlerde glukoz metabolizma bozukluğunu ve insülin direncini göstermek için bir belirteç olarak kullanılabileceğini düşünüyoruz.

Anahtar Kelimeler:

apelin 36, pre-diabet, diabet

Serum apelin-36 levels in pre-diabetics and newly diagnosed diabetes mellitus patients

Purpose: The aim of this study was to investigate the levels of parameters for glucose metabolism and cardiovascular risk factors and apelin-36 in patients grouped as having impaired fasting glucose(IFG), IFG and impaired glucose tolerance(IGT), newly diagnosed type 2 DM and the control group.Materials and Methods: Fifty-three women and twenty-seven men, totally eighty subjects were enrolled in this study. The patients were classified into four groups according to their oral glucose tolerance test (OGTT) results. Group1: Normoglycemic controls(n:20), Group2: subjects with IFG(n:20), Group3: combined IFG subjects which included both IFG and IGT patients(n:20), Group4: Newly diagnosed type 2 DM patients(n:20). Levels of glucose, lipids, HbA1c, fibrinogen, insulin, cortisol, serum apelin-36 and C-peptide were analyzed.Results: There was a statistically significant difference regarding the levels of apelin-36 between group 1 and the study groups 2, 3 and 4, respectively. Other parameters analyzed for glucose metabolism and cardiovascular risk factors such as fasting glucose, HbA1c, HOMA-IR, fibrinogen, insulin, cortisol, C-peptide, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol, triglycerides, total cholesterol were significantly higher in the study groups when compared to the control group.Conclusion: In the future serum apelin-36 levels can be used as an indicator for presenting the insulin resistance and impairment in glucose metabolism in the early periods.

Keywords:

apelin 36, pre-diabetic, diabetes,

PDF

___

1. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care. 2012;35:11–63.
2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. Circulation.2005;112:2735-52.
3. Kovanen PT, Pentikainen MO. Decorin links lowdensity lipoproteins (LDL) to collagen: a novel mechanism for retention of LDL in the atherosclerotic plaque. Trends Cardiovasc Med. 1999;9:86-91.
4. Altunkaynak BZ, Özbek E. Yağ dokusu endokrin bir organ mıdır? Dicle Tıp Dergisi. 2005;32:211-7.
5. Gimble JM. Adipose tissue-derived therapeutics. Expert opinion on biological therapy. 2003;3:705-13.
6. Tatemoto K, Takayama K, Zou M-X, Kumaki I, Zhang W, Kumano K et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99:87-92.
7. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993;136:355-60.
8. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471-6.
9. Lee DK, Cheng R, Nguyen T,Fan T, Kariyawasam AP, Liu Y et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000;74:34-41.
10. Bełtowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? Med Sci Monit Basic Res. 2006;12:RA112-9.
11. Llorens-Cortès C, Beaudet A. Apelin, a neuropeptide that counteracts vasopressin secretion. Med Sci. 2005;21:741–6.
12. Baranova A, Randhawa M, Jarrar M, Younossi ZM. Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. Expert Rev Mol Diagn. 2007;7:195- 205.
13. Medhurst AD, Jennings CA, Robbins MJ,Davis RP, Ellis C, Winborn KY et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003;84:1162-72.
14. Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, Mazzucotelli A et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146:1764-71.
15. Winzell MS, Magnusson C, Ahrén B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept. 2005;131:12-7.
16. Jin W, Su X, Xu M, Liu Y , Shi J , Lu L , et al. Interactive association of five candidate polymorphisms in Apelin/APJ pathway with coronary artery disease among Chinese hypertensive patients. PLoS One. 2012;7:e51123.
17. Kadoglou NP, Lampropoulos S, Kapelouzou A, Gkontopoulos A, Theofilogiannakos EK, Fotiadis G et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease KOZANI STUDY. Transl Res. 2010;155:238-46.
18. Li L, Zeng H, Chen J-X. Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2012;303:H605-H18.
19. Trayhurn P, Bing C, Wood IS. Adipose tissue and adipokines-energy regulation from the human perspective. J Nutr. 2006;136:1935S-9S.
20. Ziora K, Oswiecimska J, Swietochowska E, Ziora D, Ostrowska Z, Stojewska M et al. Assessment of serum apelin levels in girls with anorexia nervosa. J Clin Endocrinol Metab. 2010;95:2935-41.
21. Li L, Yang G, Li Q, Tang Y, Yang M, Yang H et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes. 2006;114:544-8.
22. International Diabetes Federation. IDF Diabetes Atlas. 7th Edition. Brussels, International Diabetes Federation, 2015.
23. Tai ES, Goh SY, Lee JJ, Wong MS, Heng D, Hughes K et al. Lowering the Criterion for Impaired Fasting Glucose Impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care. 2004;27:1728-34.
24. Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R, Nathan DM. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors results from the Baltimore longitudinal study on aging. Diabetes. 2004;53:2095-100.
25. Hollenbeck C, Reaven GM.Variations in insulinstimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab. 1987;64:1169-73.
26. Cavallo MG, Sentinelli F, Barchetta I, Costantino C, Incani M, Perra L et al. Altered glucose homeostasis is associated with increased serum apelin levels in type 2 diabetes mellitus. PloS One. 2012;7:e51236.
27. Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2008;116:289-92.
28. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB et al. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799-809.
29. Meade T, Brozovic M, Chakrabarti R, Miller GJ, Chakrabarti RR, North WR et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;328:533-7.
30. Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res. 2005;65:73- 82.
31. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail. 2006;8:355-60.
32. Ellinor PT, Low AF, MacRae CA. Reduced apelin levels in lone atrial fibrillation. Eur Heart J. 2006;27:222-6.
33. Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CC. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia reperfusion injury. Basic Res Cardiol. 2007;102:518-28.
34. Tasci I, Erdem G, Ozgur G,Tapan S, Dogru T, Genc H et al. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis. 2009;204:222-8.
35. Gourdy P, Cazals L, Thalamas C, Sommet A, Calvas F, Galitzky M et al. Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic-euglycaemic clamp. Diabetes Obes Metab. 2018;20:157-164.